1.	EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF103659, NCT00338247
2.	Phase IV Randomized Study of Doxorubicin Hydrochloride Liposome Versus Capecitabine as First-Line Chemotherapy in Women With Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: SPRI-P04445, EU-20654, NCT00266799, SPRI-PELICAN
3.	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML20592, NCT00502671
4.	Phase IV Study of Chemoresistance Markers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CHUL-BIO-COLON, RECF0356, INCA-RECF0356, NCT00559676
5.	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML21380, NCT00577031
6.	Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (= 75 Years) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 75 and over Sponsor: Other Protocol IDs: I07028, N° EudraCT : 2008-001195-7, NCT00812864
7.	Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CAP001, PDDG/CAP001, NCT00854477
8.	Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CAP002, NCT00871273
9.	Phase II/III Study of Neoadjuvant Therapy Comprising Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) (Abraxane®) in Women With Previously Untreated, Unresected, Stage II-IIIB Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WHC-MRI-GU-2006-097, NCT00397761
10.	Standard Versus Continuous Capecitabine in Advanced Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 05/237, NCT00418028
11.	Phase II/III Randomized Study of Neoadjuvant and Adjuvant Chemotherapy Comprising Epirubicin Hydrochloride, Cisplatin, and Capecitabine With or Without Bevacizumab in Patients With Previously Untreated, Resectable Gastric or Gastroesophageal Junction Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MRC-ST03, EU-20710, ISRCTN46020948, EUDRACT-2006-000811-12, CTA-00316/0221/001, NCT00450203
12.	Phase II/III Randomized Study of Chemoradiotherapy Comprising Cisplatin, Capecitabine, and Radiotherapy With or Without Cetuximab in Patients With Carcinoma of the Esophagus Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCTU-SCOPE-1, EU-20739, EUDRACT-2006-002241-37, ISRCTN47718479, CTA-17853/0202/001-0001, NCT00509561
13.	Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Active Age: 12 to 80 Sponsor: Other Protocol IDs: A-39/29.1.2007, ICMR No-5/8/7/26/99-ECD-I, NCT00522405
14.	Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to79 Sponsor: Other Protocol IDs: 2007-07-RCT-LCI1, NCT00561522
15.	Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: not specified Sponsor: Other Protocol IDs: N07MAN, Eudract 2007-007030-20, NCT00684216
16.	Phase III Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-R-04, NCT00058474, CALGB-NSABP-R-04
17.	Phase III Randomized Study of Leucovorin Calcium and Fluorouracil With or Without Oxaliplatin Versus Capecitabine With or Without Oxaliplatin in Patients With Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: NCRI-FOCUS2, MRC-CR09, EU-20303, NCT00070213
18.	Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP9881B/3001, NCT00081796
19.	Phase III Randomized Study of Neoadjuvant Chemoradiotherapy Comprising Radiotherapy and Capecitabine With Versus Without Oxaliplatin Followed By Total Mesorectal Excision in Patients With Resectable Stage II or III Rectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: FRE-FNCLCC-ACCORD-12/0405, EU-20522, NCT00227747
20.	Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: CIBOMA 2004-01, NCT00130533
21.	Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: AERO-MC04, NCT00189683
22.	Study in Elderly Patients With Early Breast Cancer (ICE) Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: GBG32, BIG 4-04, NCT00196859
23.	A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-Positive Primary Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 64 Sponsor: Other Protocol IDs: GBG 33, GAIN, NCT00196872
24.	Phase III Randomized Study of Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil (Modified FOLFOX) or Oxaliplatin and Capecitabine (XELOX) in Combination With Bevacizumab With Versus Without Erlotinib in Patients With Unresectable Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GERCOR-C04-2, EU-20565, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824, GERCOR-DREAM- C04-2
25.	Phase III Randomized Study of Neoadjuvant Epirubicin Hydrochloride, Cyclophosphamide, and Docetaxel With Versus Without Capecitabine and/or Trastuzumab (Herceptin®) Followed by Surgery in Women With Stage I-III Primary Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GBG-GEPARQUATTRO, GBG-40, EU-205101, AVENTIS-GBG-GEPARQUATTRO, ROCHE-AVENTIS-GBG-GEPARQUATTRO, EUDRACT-2005-001546-17, NCT00288002